Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe

The Lancet Psychiatry

Fecha de publicación: 1 de enero de 2022

Autores: Dragana Bugarski-Kirola, MD , Prof Celso Arango, MD, Prof Maurizio Fava, MD, Prof Henry Nasrallah, MD, I-Yuan Liu, MSc, Brandon Abbs, PhD, Srdjan Stankovic, MD

DOI: https://doi.org/10.1016/S2215-0366(21)00386-2

Background: Negative symptoms of schizophrenia are associated with adverse clinical outcomes, but there are few effective treatments. We aimed to assess the effects of pimavanserin, a selective 5-HT2A inverse agonist and antagonist, on negative symptoms of schizophrenia.

Enviar comentario